Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
VYNE similar filings
- 17 Jun 22 VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
- 17 May 22 Regulation FD Disclosure
- 12 May 22 VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
- 7 Apr 22 VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
- 30 Mar 22 VYNE Reports Positive Preclinical Data for Intra-Articular Injection of
- 17 Mar 22 VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
- 15 Mar 22 Entry into a Material Definitive Agreement
Filing view
External links
Exhibit 16.1
April 6, 2022
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by VYNE Therapeutics Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of VYNE Therapeutics Inc. dated April 6, 2022. We agree with the statements concerning our Firm contained therein.
Very truly yours,
/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey